Jove
Visualize
Contact Us
JoVE
x logofacebook logolinkedin logoyoutube logo
ABOUT JoVE
OverviewLeadershipBlogJoVE Help Center
AUTHORS
Publishing ProcessEditorial BoardScope & PoliciesPeer ReviewFAQSubmit
LIBRARIANS
TestimonialsSubscriptionsAccessResourcesLibrary Advisory BoardFAQ
RESEARCH
JoVE JournalMethods CollectionsJoVE Encyclopedia of ExperimentsArchive
EDUCATION
JoVE CoreJoVE BusinessJoVE Science EducationJoVE Lab ManualFaculty Resource CenterFaculty Site
Terms & Conditions of Use
Privacy Policy
Policies

Filters

Aika Funasaki

Showing results (11-20 of 15) with videos related to

Pageof 2
Sort By:
You have reached the last page of results.This site can display upto 15 results.
Frontiers in Oncology|June 26, 2020
Higher Tumor Mutation Burden and Higher PD-L1 Activity Predicts the Efficacy of Immune Checkpoint Inhibitor Treatment in a Patient With Four Lung Cancers. A Case ReportKatsuo Usuda, Yo Niida, Shun Iwai, et al.
Medical Oncology (Northwood, London, England)|April 11, 2018
FDG-PET/CT and diffusion-weighted imaging for resected lung cancer: correlation of maximum standardized uptake value and apparent diffusion coefficient value with prognostic factorsKatsuo Usuda, Aika Funasaki, Atsushi Sekimura, et al.
Translational Oncology|March 12, 2019
Diffusion-weighted magnetic resonance imaging is useful for the response evaluation of chemotherapy and/or radiotherapy to recurrent lesions of lung cancerKatsuo Usuda, Shun Iwai, Aika Funasaki, et al.
Cancers|June 20, 2019
Diffusion-Weighted Imaging Can Differentiate between Malignant and Benign Pleural DiseasesKatsuo Usuda, Shun Iwai, Aika Funasaki, et al.
Annals of Medicine and Surgery (2012)|July 3, 2020
Emergence of lung cancer with a low PD-L1 expression level after the administration of immune check point inhibitor for lung adenocarcinoma with a high PD-L1 expression level: A case reportShun Iwai, Aika Funasaki, Atsushi Sekimura, et al.
Pageof 2

Showing results (11-20 of 15) with videos related to

Sort By:
Pageof 2
You have reached the last page of results.This site can display upto 15 results.
Frontiers in Oncology|June 26, 2020
Higher Tumor Mutation Burden and Higher PD-L1 Activity Predicts the Efficacy of Immune Checkpoint Inhibitor Treatment in a Patient With Four Lung Cancers. A Case ReportKatsuo Usuda, Yo Niida, Shun Iwai, et al.
Medical Oncology (Northwood, London, England)|April 11, 2018
FDG-PET/CT and diffusion-weighted imaging for resected lung cancer: correlation of maximum standardized uptake value and apparent diffusion coefficient value with prognostic factorsKatsuo Usuda, Aika Funasaki, Atsushi Sekimura, et al.
Translational Oncology|March 12, 2019
Diffusion-weighted magnetic resonance imaging is useful for the response evaluation of chemotherapy and/or radiotherapy to recurrent lesions of lung cancerKatsuo Usuda, Shun Iwai, Aika Funasaki, et al.
Cancers|June 20, 2019
Diffusion-Weighted Imaging Can Differentiate between Malignant and Benign Pleural DiseasesKatsuo Usuda, Shun Iwai, Aika Funasaki, et al.
Annals of Medicine and Surgery (2012)|July 3, 2020
Emergence of lung cancer with a low PD-L1 expression level after the administration of immune check point inhibitor for lung adenocarcinoma with a high PD-L1 expression level: A case reportShun Iwai, Aika Funasaki, Atsushi Sekimura, et al.
Pageof 2